Psychiatric News
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Quicksearch
Advanced Search
Or Search All APPI Journals
Services
* Email this article to a Colleague
* Similar articles in this journal
* Alert me to new issues of the journal
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via Google Scholar
Google Scholar
* Search for Related Content
Psychiatric News November 16, 2001
Volume 36 Number 22
© 2001 American Psychiatric Association
p. 14


Professional News

Economic Impact Unclear

With antidepressant, antianxiety, and sedative medications having been dispensed in significantly increased quantities following September 11, the steadily growing portion of the health care dollar devoted to medications grew even more.

While NDCHealth provided Psychiatric News with data on the costs of the increased dispensing of these medications, no data are yet available on who is paying for the added medications—patients, third-party insurance, or state programs such as Medicaid.

Regardless of who is paying, the bill for these drugs is indeed a significant one, according to projections of the cost to the entire population based on NDCHealth’s sampling of two-thirds of the registered pharmacies nationwide. The projected cost of the additional antidepressant medications prescribed between September 11 and the week ending October 12 noted in the story above amounted to an additional $51 million compared with sales prior to the week ending September 7.

That increase pushed the total projected expenditures for all SSRIs/SNRIs nationally to $1.3 billion for that five-week period. The increase in antianxiety medications dispensed resulted in a projection of an extra $12.8 million being spent in those five weeks, increasing the total national bill for anxiety medications to nearly $300 million during that time. During the same period, projected sales of sedative/hypnotic medications increased $6.5 million relative to sales prior to September 11. That brought the projected total sales figures for sleeping pills to some $167 million.

Together the projected increase in selected psychotropic medications looked at in the NDCHealth data came to $70.3 million. During the five-week period reflected in the data, a projected total of $1.68 billion was spent on antidepressant, antianxiety, and sedative medications.





Services
* Email this article to a Colleague
* Similar articles in this journal
* Alert me to new issues of the journal
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via Google Scholar
Google Scholar
* Search for Related Content


Get information about faster international access.

Privacy Policy

Copyright © 2001 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org